<DOC>
	<DOCNO>NCT02293928</DOCNO>
	<brief_summary>The effect antiplatelet therapy impair among patient , recently underwent on-pump coronary artery bypass grafting . The impact hybrid coronary revascularization use minimal invasive surgical technique antiplatelet effect aspirin clopidogrel remain unclear . The aim study describe impact hybrid coronary revascularization effect aspirin clopidogrel . Furthermore , investigate whether high baseline platelet aggregation , high postoperative level platelet turnover acute-phase response may contribute effect .</brief_summary>
	<brief_title>Impact Hybrid Coronary Revascularization Antiplatelet Therapy</brief_title>
	<detailed_description>Objective : The effect antiplatelet therapy impair among patient , recently underwent on-pump coronary artery bypass grafting . The impact hybrid coronary revascularization use minimal invasive surgical technique antiplatelet effect aspirin clopidogrel remain unclear . We hypothesize hybrid coronary revascularization associate transiently reduce antiplatelet effect aspirin clopidogrel . We hypothesize reduced antiplatelet effect aspirin clopidogrel could explain increased platelet turnover increase fraction immature platelets peripheral blood . Furthermore , hypothesize reduce antiplatelet effect associate increase inflammatory marker early postoperative phase . We hypothesize , high platelet aggregation prior intervention associate reduced effect antiplatelet therapy follow hybrid coronary revascularization . Methods : 40 patient coronary artery disease enrol prospective cohort study ( recruit prospective pilot study conduct assess feasibility safety hybrid coronary revascularization combine minimally invasive off-pump coronary artery bypass graft inferior J-hemisternotomy ( JOPCAB ) percutaneous coronary intervention - Clinicaltrials.gov identifier : NCT01496664 ) . Demographics medical history document preoperatively . The predicted mortality assess mean logistic European System Cardiac Operative Risk Evaluation ( EuroSCORE ) I . Adverse cardiovascular event record prospectively , include graft dysfunction , myocardial infarction , stroke , pulmonary embolism . Six blood sample obtain patient : - Pre-OP : outpatient set patient aspirin 75 mg daily - Baseline : morning prior surgery eight ten day aspirin discontinuation ( off-aspirin ) - Post-OP : first postoperative day aspirin resume - Pre-PCI : day prior PCI - Post-PCI : first day PCI follow initiation dual antiplatelet therapy - 1-year follow-up : patient still maintenance aspirin 75 mg clopidogrel 75 mg Platelet function analysis perform use Multiplate® Analyzer ( Roche , Roche Diagnostics , Mannheim , Germany ) , VerifyNow® Aspirin , VerifyNow® P2Y12 ( Accumetrics Inc. , San Diego , CA , USA ) . For Multiplate® Analyzer , arachidonic acid ( 1.0 mM ) adenosine diphosphate ( 6.4 20 uM ) use agonist . Complete blood count , include immature platelet fraction ( IPF ) , immature platelet count ( IPC ) , mean platelet volume ( MPV ) , perform use Sysmex XE-5000 haematology analyzer ( Sysmex , Kobe , Japan ) upgrade software ( XE IPF Master , Sysmex ) enable flow cytometric detection IPF . Enzyme-linked immunosorbent assay use accord manufacturer ' instruction measure serum thromboxane B2 ( Cayman Chemical , Ann Arbor , MI , USA ) thrombopoietin ( R &amp; D Systems Europe , Abingdon , UK ) . Plasma C-reactive protein measure immunoprecipitation use Cobas® 6000 ( Roche , Basel , Switzerland ) . Von Willebrand factor ( antigen ) coagulation factor VIII ( functional ) measure use ACL TOP ( ILS Laboratories , Bedford , MA , USA ) .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>symptomatic multivessel coronary artery disease treatment nonenteric coat aspirin 75 mg daily aspirin clopidogrel intolerance condition prohibitive aspirin discontinuation prior surgery use anticoagulant drug aspirin know affect platelet function use immunosuppressive drug platelet count &lt; 100 &gt; 450 x 109/l inability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Hybrid coronary revascularization</keyword>
	<keyword>Antiplatelet therapy</keyword>
	<keyword>Aspirin</keyword>
	<keyword>Clopidogrel</keyword>
</DOC>